VETOQUINOL S.A financials
VETOQUINOL S.A
Country: FR Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
969500YP0AETQIK48R39 Financial statements
(EUR, as reported — unscaled; 105 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €525.7M | €539.2M |
| Employee benefits expense | €167.7M | €167.5M |
| Raw materials & consumables used | €132.3M | €150.8M |
| Operating profit (EBIT) | €78.3M | €77.3M |
| Net finance income / (cost) | €2.0M | €3.7M |
| Profit before tax | €80.3M | €81.0M |
| Income tax expense | €22.9M | €22.3M |
| Profit for the year | €57.3M | €58.7M |
| — attributable to owners | €57.4M | €58.7M |
| — attributable to NCI | -€23.0K | -€5.0K |
| Total comprehensive income | €38.8M | €62.0M |
| Per share | ||
| Basic EPS | €4.94 | €4.98 |
| Diluted EPS | €4.94 | €4.98 |
| Free cash flow / share | €4.74 | €6.05 |
| Cash flow statement | ||
| Cash generated from operations | €111.5M | €108.3M |
| Net cash from operating activities | €72.1M | €85.8M |
| Income taxes paid | €26.8M | €21.8M |
| Net cash from investing activities | -€20.6M | -€15.6M |
| Purchase of PP&E (capex) | €17.0M | €14.5M |
| Purchase of intangibles | €3.7M | €3.1M |
| Net cash from financing activities | -€25.1M | -€16.0M |
| Dividends paid | €10.4M | €10.1M |
| Proceeds from borrowings | €2.8M | €845.0K |
| Repayments of borrowings | €1.8M | €1.9M |
| Lease liability payments | €6.7M | €6.6M |
| Balance sheet | ||
| Total assets | €763.6M | €744.1M |
| Non-current assets | €305.6M | €323.0M |
| Property, plant & equipment | €81.7M | €76.6M |
| Right-of-use assets | €12.9M | €16.0M |
| Intangible assets & goodwill | €70.9M | €76.4M |
| Current assets | €458.0M | €421.2M |
| Inventories | €122.0M | €112.3M |
| Trade & other receivables | €99.0M | €94.8M |
| Cash & equivalents | €221.1M | €206.3M |
| Total equity | €591.4M | €575.9M |
| — attributable to owners | €591.4M | €575.8M |
| Non-controlling interests | €69.0K | €92.0K |
| Non-current liabilities | €23.5M | €26.7M |
| Long-term borrowings | €158.0K | €178.0K |
| Lease liabilities (non-current) | €8.2M | €11.0M |
| Current liabilities | €148.7M | €141.5M |
| Lease liabilities (current) | €5.3M | €5.5M |
| Trade & other payables | €134.8M | €128.4M |
| Deferred tax liabilities | €5.2M | €6.0M |
| Derived metrics | ||
| Free cash flow | €55.1M | €71.3M |
| Operating margin | 14.9% | 14.3% |
| Net margin | 10.9% | 10.9% |
| Return on equity | 9.7% | 10.2% |
| Cash conversion ratio | 1.26× | 1.46× |
| Capex coverage | 4.23× | 5.90× |
| Other reported items | ||
| Adjustments For Income Tax Expense | €22.9M | €22.3M |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | €170.0K | €159.0K |
| Adjustments For Interest Expense | €594.0K | €591.0K |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -€16.0K | €511.0K |
| Adjustments For Sharebased Payments | €0 | €0 |
| Adjustments For Undistributed Profits of Associates | €0 | €0 |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €221.0M | €202.4M |
| Cash and Cash Equivalents In Subsidiary Or Businesses Acquired Or Disposed2013 | €0 | €0 |
| Comprehensive Income Attributable To Noncontrolling Interests | -€23.0K | -€5.0K |
| Comprehensive Income Attributable To Owners of Parent | €38.9M | €62.0M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €1.6M | €4.4M |
| Current Tax Assets Current | €10.7M | €3.1M |
| Current Tax Liabilities Current | €5.5M | €2.7M |
| Deferred Tax Assets | €9.0M | €10.3M |
| Depreciation Rightofuse Assets | €6.2M | €6.1M |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | €10.4M | €10.1M |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | €0 | €0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€7.9M | €2.1M |
| Equity and Liabilities | €763.6M | €744.1M |
| Increase Decrease In Cash and Cash Equivalents | €18.5M | €56.2M |
| Increase Decrease In Working Capital | -€12.7M | -€630.0K |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Exercise of Options | €0 | €0 |
| Increase Decrease Through Transfers and Other Changes Equity | €1.0K | -€48.0K |
| Increase Decrease Through Treasury Share Transactions | -€12.9M | -€3.1M |
| Intangible Assets Other Than Goodwill | €129.7M | €142.1M |
| Interest Expense | -€4.0M | -€4.6M |
| Interest Expense On Lease Liabilities | €594.0K | €591.0K |
| Interest Income On Cash and Cash Equivalents | €5.3M | €5.9M |
| Interest Paid Classified As Financing Activities | €661.0K | €481.0K |
| Investment Accounted For Using Equity Method | €0 | €0 |
| Liabilities | €172.2M | €168.2M |
| Liabilities Included In Disposal Groups Classified As Held For Sale | €0 | €0 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | €0 | €0 |
| Noncurrent Provisions For Employee Benefits | €8.1M | €8.0M |
| Other Adjustments For Noncash Items | €0 | €0 |
| Other Comprehensive Income | -€18.5M | €3.4M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€18.6M | €3.2M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €123.0K | €113.0K |
| Other Current Nonfinancial Assets | €5.2M | €4.6M |
| Other Current Nonfinancial Liabilities | €1.0K | €1.0K |
| Other Finance Cost | €9.8M | €6.0M |
| Other Finance Income | €7.7M | €4.8M |
| Other Inflows Outflows of Cash Classified As Financing Activities | €0 | €0 |
| Other Longterm Provisions | €1.3M | €746.0K |
| Other Noncurrent Financial Assets | €1.5M | €1.5M |
| Other Noncurrent Nonfinancial Liabilities | €601.0K | €686.0K |
| Other Shortterm Provisions | €1.5M | €502.0K |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €209.0K | €2.1M |
| Proceeds From Government Grants Classified As Financing Activities | €0 | €0 |
| Proceeds From Issuing Shares | €0 | €0 |
| Purchase of Financial Instruments Classified As Investing Activities | €8.0K | €2.0K |
| Retained Earnings Profit Loss For Reporting Period | €57.4M | €58.7M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €0 | €0 |
| Tax Expense Other Than Income Tax Expense | €8.2M | €7.6M |
Methodology
Every line item above is a fact tagged in VETOQUINOL S.A's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.